ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2009
Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Studies Comparing the Measurement Properties of the Three-Level and Five-Level Versions of the EQ-5D.PharmacoEconomics · 2018Pooled it
- Long-term utility outcomes in patients undergoing endoscopic sinus surgery.The Laryngoscope · 2014Trial
- Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial.PharmacoEconomics · 2010Trial
- Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among patients with diabetes in China.Health and quality of life outcomes · 2025Article
- Population Norms for the EQ-5D-5L, PROPr and SF-6D in Hungary.PharmacoEconomics · 2024Article
- Understanding the CRSwNP Patient as Whole.American journal of rhinology & allergy · 2023Review
- Patient-reported sleep outcomes lack association with mucosal eosinophilia or neutrophilia in patients with chronic rhinosinusitis undergoing functional endoscopic sinus surgery.International forum of allergy & rhinology · 2021Article
- Comparison of EuroQol-5D-3L and Short Form-6D Utility Scores in Family Caregivers of Colorectal Cancer Patients: A Cross-Sectional Survey in China.Frontiers in public health · 2021Article
- Psychometric Validation of the EQ-5D-3L in Patients with Nontuberculous Mycobacterial (NTM) Lung Disease Caused byPatient related outcome measures · 2021Article
- Validity of EQ-5D utility index and minimal clinically important difference estimation among patients with chronic obstructive pulmonary disease.BMC pulmonary medicine · 2020Article
- Sleep disruption in chronic rhinosinusitis.Expert review of anti-infective therapy · 2017Review
- EQ-5D in Central and Eastern Europe: 2000-2015.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2016Review
- Article
- Comparison of EQ-5D and SF-6D utilities in Pompe disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2015Article
- Factors associated with quality of life measured by EQ-5D in patients with nontuberculous mycobacterial pulmonary disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2014Article
- Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems.Health and quality of life outcomes · 2014Observational
- A comparison between the EQ-5D and the SF-6D in patients with chronic obstructive pulmonary disease (COPD).PloS one · 2014Article
- Article
- The association between asthma control, health care costs, and quality of life in France and Spain.BMC pulmonary medicine · 2013Article
- Exacerbation-related impairment of quality of life and work productivity in severe and very severe chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2013Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of this study was to understand systematic differences in utility values derived from the EQ-5D and the SF-6D in two respiratory populations with heterogeneous disease severity.
methodsThis study involved secondary analysis of data from two cross-sectional surveys of patients with asthma (N = 228; Hungary) and COPD (N = 176; Sweden). Disease severity was defined according to GINA and GOLD guidelines for asthma and COPD, respectively. EQ-5D and SF-6D scores and their distributional characteristics were compared across the two samples by disease severity level.
resultsWithin each patient population, mean EQ-5D and SF-6D scores were similar for the overall group and for those with moderate disease. Mean scores varied for patients with mild and severe disease. EQ-5D versus SF-6D scores in the asthma group by severity levels were 0.89 versus 0.80, 0.70 versus 0.73, 0.63 versus 0.64, and 0.51 versus 0.63, respectively. EQ-5D versus SF-6D scores in the COPD group by severity levels were 0.85 versus 0.80, 0.73 versus 0.73, 0.74 versus 0.73, and 0.53 versus 0.62, respectively.
conclusionsResults suggest the EQ-5D and SF-6D do not yield consistent utility values in patients with asthma and COPD due to differences in underlying valuation techniques and the EQ-5D's limited response options relative to mild disease.
Indexed as
Identifiers
19105049What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.